Sept. 15, 2008 — The FDA has approved Sancuso, a five-day fix that battles queasiness from cancer chemotherapy.
Sancuso ceaselessly conveys a relentless measurements of a sedate called granisetron, which pieces serotonin receptors and makes a difference prevent queasiness.
Queasiness may be a common side effect of chemotherapy. Not all chemotherapy patients experience this side impact, but it can be life- threatening. A few patients got to rashly stop their cancer treatment since of severe nausea and vomiting.
Granisetron, delivered by injection or orally through tablets or solution, is sold beneath the brand name Kytril by Roche Pharmaceuticals. The Sancuso patch is from Scotland-based ProStrakan International.
“A fix that can be applied before treatment, releasing medicine reliably into the circulatory system over a number of days, has the potential to affect patient consolation and quality of life,” oncology nurse practitioner Barbara Rogers, CRNP, of Fox Chase Cancer Center, said in a ProStrakan news release.
The transparent Sancuso fix is applied to the upper arm.
The FDA endorsement was based on results from a Phase III clinical trial in which Sancuso was compared with once-daily oral granisetron and fake treatment. The patch prevented chemotherapy-induced sickness and heaving as well as the oral item did, concurring to the company news release.
The foremost imperative Sancuso side impact in the clinical trial was constipation. Overall, nearly 9% of patients experienced unfavorable responses related to the drug, but the medicate was for the most part well endured.
Concurring to the FDA, Sancuso may be used to prevent queasiness and vomiting in patients accepting nausea-inducing chemotherapy regimens for up to five successive days.
ProStrakan says Sancuso ought to be accessible to patients in December.